Matt Davidson

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
West Chester, PA
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Matthew Gene Davidson
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Matt Davidson

Form 4 holding Chief Development Officer, Director

ADIAL PHARMACEUTICALS, INC.

Security class
Stock Option (Right to Buy)
Shares / value
232,417
Estimated value
Report date
12 Jun 2026
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Chief Development Officer, Director

ADIAL PHARMACEUTICALS, INC.

Security class
Series A Preferred Stock
Shares / value
1,923
Estimated value
Report date
11 Jun 2026
Price
Ownership
By Matt and Alli Davidson Trust
Form 4 holding Chief Development Officer, Director

ADIAL PHARMACEUTICALS, INC.

Security class
Series A Preferred Stock
Shares / value
1,822
Estimated value
Report date
11 Jun 2026
Price
Ownership
Direct

Insider Reports Filed by Matt Davidson

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .